BA
GSK icon

Bridgewater Associates’s GSK GSK Stock Holding History

Bridgewater Associates’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.4M Sell
504,171
-194,495
-28% -$10.3M 0.11% 157
2026
Q1 		$38.6M Sell
698,666
-717,859
-51% -$38.9M 0.17% 89
2025
Q4 		$69.5M Buy
1,416,525
+14,770
+1% +$689K 0.25% 67
2025
Q3 		$60.5M Buy
1,401,755
+57,713
+4% +$2.25M 0.24% 75
2025
Q2 		$51.6M Buy
1,344,042
+140,947
+12% +$5.39M 0.21% 86
2025
Q1 		$46.6M Sell
1,203,095
-1,044,596
-46% -$38.2M 0.22% 96
2024
Q4 		$76M Buy
2,247,691
+1,281,855
+133% +$46.1M 0.35% 54
2024
Q3 		$39.5M Buy
965,836
+500,010
+107% +$20.5M 0.22% 83
2024
Q2 		$17.9M Buy
465,826
+330,532
+244% +$13.9M 0.09% 165
2024
Q1 		$5.8M Sell
135,294
-78,726
-37% -$3.25M 0.03% 357
2023
Q4 		$7.93M Buy
214,020
+35,982
+20% +$1.29M 0.04% 289
2023
Q3 		$6.45M Sell
178,038
-13,099
-7% -$465K 0.04% 311
2023
Q2 		$6.81M Buy
191,137
+36,485
+24% +$1.31M 0.04% 252
2023
Q1 		$5.5M Buy
154,652
+21,674
+16% +$758K 0.03% 292
2022
Q4 		$4.67M Buy
132,978
+45,317
+52% +$1.51M 0.03% 373
2022
Q3 		$2.58M Buy
87,661
+14,332
+20% +$543K 0.01% 508
2022
Q2 		$3.99M Sell
73,329
-5,232
-7% -$289K 0.02% 547
2022
Q1 		$4.28M Buy
78,561
+4,291
+6% +$233K 0.02% 507
2021
Q4 		$4.09M Sell
74,270
-21,442
-22% -$1.12M 0.02% 339
2021
Q3 		$4.57M Buy
95,712
+5,042
+6% +$253K 0.03% 302
2021
Q2 		$4.51M Buy
+90,670
New +$4.36M 0.03% 351

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Bridgewater Associates's GSK Position: Q2 2026 in Review

Bridgewater Associates reduced its GSK (GSK) stake by 28% in Q2 2026, selling an estimated $10.3M and leaving 504,171 shares worth $26.4M. The position accounts for 0.11% of the portfolio, ranked #157.

Bridgewater Associates first reported a position in GSK in Q2 2021 and has held it in 21 quarters since. The position peaked at $76M in Q4 2024. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Bridgewater Associates held 504,171 shares of GSK worth $26.4M as of Q2 2026.
  • Bridgewater Associates sold 194,495 GSK shares in Q2 2026, an estimated $10.3M.
  • GSK made up 0.11% of Bridgewater Associates's portfolio in Q2 2026, its #157 holding.
  • Bridgewater Associates first reported a position in GSK in Q2 2021 and has held it in 21 quarters since.
  • Bridgewater Associates's GSK position peaked at $76M in Q4 2024.
  • 1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Bridgewater Associates's 13F filing for Q2 2026, filed 14 Aug 2026.